REPL - Replimune Group, Inc.

QQQ $ 441.33 $ 0.96 (0.22 %)

DIA $ 394.43 $ 3.52 (0.9 %)

SPY $ 520.56 $ 2.98 (0.58 %)

TLT $ 90.69 $ 0.44 (0.49 %)

GLD $ 219.78 $ 0.00 (0 %)

Previous Close

$ 6.73

Open

$ 6.74

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 6.70 - $ 6.79

52 Week Range

$ 5.86 - $ 24.81

Volume

520,383

Average Volume

Market Cap

448.53M

Beta (5Y Monthly)

$ 1.26

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-08-2024	12-31-2023	10-Q
2	11-07-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-18-2023	03-31-2023	10-K
5	02-09-2023	12-31-2022	10-Q
6	11-03-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-19-2022	03-31-2022	10-K
9	02-03-2022	12-31-2021	10-Q
10	11-04-2021	09-30-2021	10-Q
11	08-06-2021	06-30-2021	10-Q
12	05-20-2021	03-31-2021	10-K
13	02-04-2021	12-31-2020	10-Q
14	11-05-2020	09-30-2020	10-Q
15	08-07-2020	06-30-2020	10-Q
16	06-03-2020	03-31-2020	10-K
17	02-13-2020	12-31-2019	10-Q
18	11-12-2019	09-30-2019	10-Q
19	08-14-2019	06-30-2019	10-Q
20	06-28-2019	03-31-2019	10-K
21	02-14-2019	12-31-2018	10-Q
22	11-14-2018	09-30-2018	10-Q
23	08-30-2018	06-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Replimune Group Presented The Interim Resu...
04/08/2024 06:21:02

In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent...

Replimune Appoints Sushil Patel To CEO Suc...
03/26/2024 11:35:24

Replimune Group: Q3 Earnings Insights
02/08/2024 13:10:05

Replimune Group Q3 EPS $(0.77) Beats $(0.9...
02/08/2024 13:03:56

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.9...

Barclays Maintains Overweight Rating for R...
12/06/2023 17:00:28

Barclays Maintains Overweight on Replimune...
12/06/2023 11:36:17

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $50...

crude-oil-moves-lower-autozone-profit-tops-views

Crude Oil Moves Lower; AutoZone Profit Top...
12/05/2023 19:27:49

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0...

Why Daktronics Shares Are Trading Lower By...
12/05/2023 18:06:18

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
12/05/2023 17:31:07

dow-falls-100-points-ism-services-pmi-increases-in-november

Dow Falls 100 Points; ISM Services PMI Inc...
12/05/2023 17:11:48

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded...

us-stocks-down-jm-smucker-posts-upbeat-earnings

US Stocks Down; JM Smucker Posts Upbeat Ea...
12/05/2023 14:39:45

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market openi...

whats-going-on-with-cancer-focused-replimune-stock-today

What's Going On With Cancer-Focused Replim...
12/05/2023 13:49:55

Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combinati...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
12/05/2023 13:07:35

Replimune Shares Initial Primary Analysis ...
12/05/2023 12:01:27

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of ...

HC Wainwright & Co. Maintains Buy on Repli...
11/13/2023 23:07:34

HC Wainwright & Co. analyst Robert Burns maintains Replimune Group (NASDAQ:REPL) with a Buy and lowers the price target ...

Wedbush Reiterates Outperform on Replimune...
11/08/2023 14:14:55

Wedbush analyst Robert Driscoll reiterates Replimune Group (NASDAQ:REPL) with a Outperform and maintains $52 price target.

Replimune Presents Updated Data On RP2 In ...
11/08/2023 14:14:00

Treatment with RP2 led to an overall response rate (ORR) of 29.4 percent (5 of 17 patients; one of the responding patients was ...

8-health-care-stocks-whale-activity-in-todays-session

8 Health Care Stocks Whale Activity In Tod...
11/07/2023 17:35:25

Replimune Group Q2 EPS $(0.90) Misses $(0....
11/07/2023 13:06:27

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0...

Replimune Announces Appointment Of Emily H...
09/19/2023 12:07:18

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of ...